Literature DB >> 34446852

Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors.

Yu-Zhe Wang1,2, De-Hua Yang3,4,5, Ming-Wei Wang6,7,8,9.   

Abstract

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are regarded as 'incretins' working closely to regulate glucose homeostasis. Unimolecular dual and triple agonists of GLP-1R and GIPR have shown remarkable clinical benefits in treating type 2 diabetes. However, their pharmacological characterization is usually carried out in a single receptor-expressing system. In the present study we constructed a co-expression system of both GLP-1R and GIPR to study the signaling profiles elicited by mono, dual and triple agonists. We show that when the two receptors were co-expressed in HEK 293T cells with comparable receptor ratio to pancreatic cancer cells, GIP predominately induced cAMP accumulation while GLP-1 was biased towards β-arrestin 2 recruitment. The presence of GIPR negatively impacted GLP-1R-mediated cAMP and β-arrestin 2 responses. While sharing some common modulating features, dual agonists (peptide 19 and LY3298176) and a triple agonist displayed differentiated signaling profiles as well as negative impact on the heteromerization that may help interpret their superior clinical efficacies.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  LY3298176; glucagon-like peptide-1 receptor; glucose-dependent insulinotropic peptide receptor; heteromerization; peptide 19; type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 34446852      PMCID: PMC9159978          DOI: 10.1038/s41401-021-00758-6

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  34 in total

Review 1.  Role of β-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking.

Authors:  Dong Soo Kang; Xufan Tian; Jeffrey L Benovic
Journal:  Curr Opin Cell Biol       Date:  2013-12-14       Impact factor: 8.382

Review 2.  Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.

Authors:  Matthias H Tschöp; Brian Finan; Christoffer Clemmensen; Vasily Gelfanov; Diego Perez-Tilve; Timo D Müller; Richard D DiMarchi
Journal:  Cell Metab       Date:  2016-07-12       Impact factor: 27.287

3.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Authors:  L A Scrocchi; T J Brown; N MaClusky; P L Brubaker; A B Auerbach; A L Joyner; D J Drucker
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

4.  Activation of the GLP-1 receptor by a non-peptidic agonist.

Authors:  Peishen Zhao; Yi-Lynn Liang; Matthew J Belousoff; Giuseppe Deganutti; Madeleine M Fletcher; Francis S Willard; Michael G Bell; Michael E Christe; Kyle W Sloop; Asuka Inoue; Tin T Truong; Lachlan Clydesdale; Sebastian G B Furness; Arthur Christopoulos; Ming-Wei Wang; Laurence J Miller; Christopher A Reynolds; Radostin Danev; Patrick M Sexton; Denise Wootten
Journal:  Nature       Date:  2020-01-08       Impact factor: 49.962

5.  Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion.

Authors:  Yukihiro Fujita; Rhonda D Wideman; Ali Asadi; Gary K Yang; Robert Baker; Travis Webber; Tianjiao Zhang; Rennian Wang; Ziliang Ao; Garth L Warnock; Yin Nam Kwok; Timothy J Kieffer
Journal:  Gastroenterology       Date:  2010-02-04       Impact factor: 22.682

6.  Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

Authors:  R A Pederson; M Satkunarajah; C H McIntosh; L A Scrocchi; D Flamez; F Schuit; D J Drucker; M B Wheeler
Journal:  Diabetes       Date:  1998-07       Impact factor: 9.461

7.  The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.

Authors:  Juan Pablo Frias; Edward J Bastyr; Louis Vignati; Matthias H Tschöp; Christophe Schmitt; Klara Owen; Rune Haubo Christensen; Richard D DiMarchi
Journal:  Cell Metab       Date:  2017-08-01       Impact factor: 27.287

8.  Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.

Authors:  M Nagashima; T Watanabe; M Terasaki; M Tomoyasu; K Nohtomi; J Kim-Kaneyama; A Miyazaki; T Hirano
Journal:  Diabetologia       Date:  2011-07-24       Impact factor: 10.122

Review 9.  Molecular Pharmacology of the Incretin Receptors.

Authors:  Suleiman Al-Sabah
Journal:  Med Princ Pract       Date:  2015-06-20       Impact factor: 1.927

10.  Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.

Authors:  Sigrid Jall; Stephan Sachs; Christoffer Clemmensen; Brian Finan; Frauke Neff; Richard D DiMarchi; Matthias H Tschöp; Timo D Müller; Susanna M Hofmann
Journal:  Mol Metab       Date:  2017-03-01       Impact factor: 7.422

View more
  1 in total

1.  Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.

Authors:  Bashaier Al-Zaid; Siby Chacko; Charles Ifeamalume Ezeamuzie; Moritz Bünemann; Cornelius Krasel; Tina Karimian; Peter Lanzerstorfer; Suleiman Al-Sabah
Journal:  Pharmacol Res Perspect       Date:  2022-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.